Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor (TCR) recognizing Dolichovespula maculata (white-faced hornet) venom peptides is a heterodimeric surface protein essential for the recognition of hornet allergens presented by Major Histocompatibility Complex (MHC) molecules (Janeway et al., Immunobiology, 2001). In sensitized individuals, these TCRs primarily interact with peptides derived from major allergens like Dol m 5 (Antigen 5) and Dol m 1 (Phospholipase A1) (WHO/IUIS Allergen Nomenclature Sub-Committee, 2024). This interaction initiates a Th2-polarized immune response, leading to the production of allergen-specific IgE and the potential for systemic anaphylaxis upon subsequent stings (Golden, J. Allergy Clin. Immunol., 2005). Therapeutically, this TCR is the target of venom immunotherapy (VIT), which utilizes standardized venom extracts to induce immune tolerance (Bousquet et al., J. Allergy Clin. Immunol., 1987). The mechanism involves shifting the T-cell response from a Th2 profile to a Th1 or regulatory T-cell (Treg) profile, characterized by increased production of IL-10 and TGF-beta (Akdis et al., J. Clin. Invest., 1998). Successful modulation of this target results in a shift from an allergic Th2 profile to a protective Th1 or Treg profile, significantly reducing the risk of life-threatening reactions upon future stings (Ruëff et al., Allergy, 2005).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Dolichovespula maculata venom peptides presented by MHC (TCR).